Shire's Gaucher drug has edge over rival in trial

LONDON Thu Jun 28, 2012 4:04pm IST

Related Topics

Stocks

   

LONDON (Reuters) - Shire's Gaucher disease drug Vpriv significantly improved lumbar spine bone density, while Sanofi's Cerezyme did not, according to results from a head-to-head clinical trial presented on Thursday.

The findings from the Shire-sponsored study, made public at a European Working Group on Gaucher Disease in Paris, may help Shire differentiate its product from Cerezyme, which is made by Sanofi's Genzyme unit.

Gaucher disease is a rare genetic disorder affecting some 10,000 patients worldwide. Patients with the disease are deficient in an enzyme that breaks down a certain type of fat, leading to potentially life-threatening organ damage and bone problems.

For many years Genzyme dominated the Gaucher market with its drug Cerezyme, at one point the most expensive drug in the world costing more than $200,000 a year.

But competition is now increasing. In addition to Vpriv, there is also another Gaucher drug called Elelyso from Protalix Biotherapeutics and Pfizer, which was approved by U.S. regulators in May but was rebuffed in Europe last week.

Ari Zimran of the Hebrew University and Hadassah Medical School, Jerusalem, said the study results showed Vpriv was effective in treating key markers of Gaucher-related bone disease.

Clinically and statistically significant improvements in bone measurements were seen at nine months of treatment with Vpriv but not with Cerezyme.

(Reporting by Ben Hirschler)

FILED UNDER:

Reuters Showcase

Killer Unmasked

Killer Unmasked

'Jihadi John' killer from Islamic State beheading videos unmasked as Londoner.  Read | Video 

DLF Penalty

DLF Penalty

DLF says reviewing $8.4 million SEBI penalty.  Full Article 

Fresh Charges

Fresh Charges

Canadian woman accuses Bikram yoga founder of sexual assault.  Full Article 

Maid Abuse Case

Maid Abuse Case

Hong Kong woman jailed for six years for abusing Indonesian maid.  Full Article 

India's Growth Story

India's Growth Story

S&P raises India's GDP forecasts, says it's a bright spot in Asia.  Full Article 

Net Rules

Net Rules

Tougher Internet rules to hit cable, telecoms companies.  Full Article 

World Cup 2015

World Cup 2015

Full coverage of cricket world cup in Australia and New Zealand.  Full Coverage 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device.  Full Coverage